Valuation: MindWalk Holdings Corp.

Market Cap 46.18M 32.24M 29.37M 27.06M 24.61M 2.99B 48.53M 329M 131M 1.63B 121M 118M 5.12B P/E 2027 *
-2.33x
P/E 2028 * -2.7x
Enterprise Value 46.18M 32.24M 29.37M 27.06M 24.61M 2.99B 48.53M 329M 131M 1.63B 121M 118M 5.12B EV / Sales 2027 *
2.63x
EV / Sales 2028 * 2.14x
Free-Float
90.75%
Yield 2027 *
-
Yield 2028 * -
11-17 Mindwalk Holdings Corp. Closes USD 30 Million Senior Unsecured Revolving Credit Facility CI
11-04 MindWalk Holdings Corp. Announces Agreement With Teva Pharmaceuticals Australia Pty Ltd To Support Defined Antibody-Discovery Workflows CI
10-23 Mindwalk Holdings Corp. Announces Departure of Thomas Lynch as Chief Business Officer, Effective October 16, 2026 CI
10-21 MindWalk Holdings Corp., NVIDIA Corporation, Absci Corporation And AbCellera Biologics Inc. Provide Product Updates For LensAI, BioNeMo Agent Toolkit, ABS-201 And ABCL635 CI
10-14 Mindwalk Holdings Corp. Announces Management Changes CI
10-06 MindWalk Holdings Corp. Outlines ReefIQ As Biological Context Layer For Life Sciences Powered By HYFT Technology CI
10-01 MindWalk Holdings Corp. Announces Appointment of Kim Remizowski as Independent Director, Audit Committee Member and Compensation, Nomination and Governance Committee Member, Effective September 29, 2026 CI
09-21 Mindwalk Holdings Corp. Brings Openfold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine CI
09-15 MindWalk Holdings Corp., Q1 2027 Earnings Call, Sep 14, 2026
09-15 MindWalk Fiscal Q1 Loss Widens, Revenue Rises MT
09-14 MindWalk Holdings Corp. Reports Earnings Results for the First Quarter Ended July 31, 2026 CI
09-14 Mindwalk Holdings Corp. Enters into Binding Commitment for USD 30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion CI
07-23 Tranche Update on MindWalk Holdings Corp.'s Equity Buyback Plan announced on October 9, 2025. CI
1 day-14.27%
1 week-30.87%
Current month-39.43%
1 month-46.95%
3 months-50.04%
6 months-56.96%
Current year-62.40%
1 week 0.64
Extreme 0.64
0.98
1 month 0.64
Extreme 0.64
1.3
Current year 0.64
Extreme 0.64
2.99
1 year 0.64
Extreme 0.64
2.99
3 years 0.27
Extreme 0.27
3.25
5 years 0.27
Extreme 0.27
6.88
10 years 0.27
Extreme 0.27
33.34
Manager TitleAgeSince
Chief Executive Officer - 21/02/2018
Director of Finance/CFO 62 20/10/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 24/05/2018
Chairman - -
Director/Board Member 56 07/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
8/19/26 A Option

Executive/Senior Manager

-12,500 0.0271%
8/19/26 A Option

Responsable ventes & marketing

7,443 0.0161%
8/19/26 A Option

Executive/Senior Manager

8,473 0.0184%
Change 5-day change 1-year change 3-year change Capi.($)
-14.27%-30.87%-61.33%-50.76% 32.27M
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average -1.10%-7.37%+18.20%+62.70% 407B
Weighted average by Cap. +0.40%-5.19%+28.03%+87.49%

Financials

2027 *2028 *
Net sales 17.56M 12.26M 11.17M 10.29M 9.36M 1.14B 18.45M 125M 49.77M 620M 46M 45.03M 1.95B 21.59M 15.07M 13.73M 12.65M 11.51M 1.4B 22.69M 154M 61.19M 762M 56.55M 55.36M 2.39B
Net income -19.36M -13.52M -12.31M -11.34M -10.32M -1.25B -20.35M -138M -54.88M -684M -50.72M -49.65M -2.15B -17.23M -12.03M -10.96M -10.1M -9.19M -1.11B -18.11M -123M -48.85M -609M -45.15M -44.19M -1.91B
Net Debt - -
Projected Income Statement - Annual - MindWalk Holdings Corp.
Logo MindWalk Holdings Corp.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Employees
76
Date Price Change Volume
20/11/26 $0.6844 -14.27% 693,950
19/11/26 $0.7983 -11.30% 416,425
18/11/26 $0.9000 -0.74% 353,193
17/11/26 $0.9067 -3.32% 242,394
16/11/26 $0.9378 -5.27% 108,206
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MindWalk Holdings Corp.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.6844USD
Average target price
4.333USD
Spread / Average Target
+533.16%
  1. Stock Market
  2. Stocks
  3. HYFT Stock